Is RNA manipulation a viable therapy for spinal muscular atrophy?

[1]  J. Fyfe,et al.  Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  J. Lu,et al.  Controlled delivery of antisense oligonucleotides: a brief review of current strategies , 2009, Expert opinion on drug delivery.

[3]  G. Lutz,et al.  Oligonucleotide-Mediated Survival of Motor Neuron Protein Expression in CNS Improves Phenotype in a Mouse Model of Spinal Muscular Atrophy , 2009, The Journal of Neuroscience.

[4]  R. Mandel,et al.  AAV9: a potential blood-brain barrier buster. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  C. Lorson,et al.  Development of a Single Vector System that Enhances Trans-Splicing of SMN2 Transcripts , 2008, PloS one.

[6]  Kenneth I. Berns,et al.  Gene Therapy Using Adeno-Associated Virus Vectors , 2008, Clinical Microbiology Reviews.

[7]  R. Juliano,et al.  Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides , 2008, Nucleic acids research.

[8]  T. Rana,et al.  Therapeutic Gene Silencing Delivered by a Chemically Modified Small Interfering RNA against Mutant SOD1 Slows Amyotrophic Lateral Sclerosis Progression*♦ , 2008, Journal of Biological Chemistry.

[9]  O. Danos,et al.  AAV vectors for RNA-based modulation of gene expression , 2008, Gene Therapy.

[10]  A. MacMillan,et al.  Pre-mRNA splicing: a complex picture in higher definition. , 2008, Trends in biochemical sciences.

[11]  Ruiwen Zhang,et al.  Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible? , 2008, Drug discovery today.

[12]  T. Flotte,et al.  Clinical gene therapy using recombinant adeno-associated virus vectors , 2008, Gene Therapy.

[13]  Y. Hua,et al.  Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. , 2008, American journal of human genetics.

[14]  Douglas L Black,et al.  Polypyrimidine tract binding protein controls the transition from exon definition to an intron defined spliceosome , 2008, Nature Structural &Molecular Biology.

[15]  J. Manley,et al.  hnRNP A1 functions with specificity in repression of SMN2 exon 7 splicing. , 2007, Human molecular genetics.

[16]  In-Kyu Park,et al.  Nonviral Approaches for Neuronal Delivery of Nucleic Acids , 2007, Pharmaceutical Research.

[17]  David V. Schaffer,et al.  Designer Gene Delivery Vectors: Molecular Engineering and Evolution of Adeno-Associated Viral Vectors for Enhanced Gene Transfer , 2007, Pharmaceutical Research.

[18]  C. Lorson,et al.  Restoration of SMN function: delivery of a trans-splicing RNA re-directs SMN2 pre-mRNA splicing. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  B. Rothen‐Rutishauser,et al.  Spinal muscular atrophy: SMN2 pre-mRNA splicing corrected by a U7 snRNA derivative carrying a splicing enhancer sequence. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  B. Davidson,et al.  Transvascular delivery of small interfering RNA to the central nervous system , 2007, Nature.

[21]  Brenda F Baker,et al.  Enhancement of SMN2 Exon 7 Inclusion by Antisense Oligonucleotides Targeting the Exon , 2007, PLoS biology.

[22]  J. Manley,et al.  An intronic element contributes to splicing repression in spinal muscular atrophy , 2007, Proceedings of the National Academy of Sciences.

[23]  C. Lorson,et al.  Stimulating full-length SMN2 expression by delivering bifunctional RNAs via a viral vector. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  Eric Hahnen,et al.  Spinal muscular atrophy: from gene to therapy. , 2006, Seminars in pediatric neurology.

[25]  R. Mandel,et al.  Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[26]  Francisco Tirado,et al.  Modulating the Expression of Disease Genes with RNA-Based Therapy , 2006, BMC Bioinformatics.

[27]  E. Androphy,et al.  Splicing of a Critical Exon of Human Survival Motor Neuron Is Regulated by a Unique Silencer Element Located in the Last Intron , 2006, Molecular and Cellular Biology.

[28]  T. Geib,et al.  Correction of SMN2 Pre-mRNA splicing by antisense U7 small nuclear RNAs. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[29]  J. Brotchi,et al.  Recombinant AAV‐mediated gene delivery to the central nervous system , 2004, The journal of gene medicine.

[30]  Christof von Kalle,et al.  A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. , 2003, The New England journal of medicine.

[31]  Sharlene R. Lim,et al.  Modulation of Survival Motor Neuron Pre-mRNA Splicing by Inhibition of Alternative 3′ Splice Site Pairing* , 2001, The Journal of Biological Chemistry.

[32]  J. Melki,et al.  The role of the SMN gene in proximal spinal muscular atrophy. , 1998, Human molecular genetics.

[33]  K. Foust,et al.  Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes , 2009, Nature Biotechnology.

[34]  Elisa de Stanchina,et al.  Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2. , 2006, American journal of human genetics.